HRMC discontinues Regeneron monclonal antibody infusions

Posted 1/21/22

Effective today, Jan. 21, 2022, HRMC will no longer offer Regeneron monoclonal antibody infusions.

You must be a member to read this story.

Join our family of readers for as little as $5 per month and support local, unbiased journalism.


Already have an account? Log in to continue. Otherwise, follow the link below to join.

Please log in to continue

Log in
I am anchor

HRMC discontinues Regeneron monclonal antibody infusions

Posted
CLEWISTON -- HRMC  no longer offers Regeneron monoclonal antibody infusions.

Based on recent data and assessment by the U.S. Food and Drug Administration (FDA) and changes in the Emergency Use Authorization (EUA) it was determined the use of Regeneron is not effective on the COVID-19 omicron variant.

U.S. Department of Health & Human Service (HHS) data shows that in Region 4, which includes Hendry County, the dominant COVID-19 variant is omicron at 99.7% of all cases, and the current community positivity rate is over 40%.

Following FDA EAU guidance and the prevalence of omicron in our area we are suspending Regeneron infusions effective immediately.

HRMC is working diligently with local, state, and federal entities to source newly identified and approved effective treatments for the use of mild to moderate COVID-19 omicron variant infections.
. . . . . . . . . .

A partir de hoy, Jan. 21, 2022, HRMC ya no ofrecerá infusiones de anticuerpos monoclonales de Regeneron.

Según datos y evaluaciones recientes de la Administración de Alimentos y Medicamentos (FDA) de EE. UU. y los cambios en la Autorización de uso de emergencia (EUA), se determinó que el uso de Regeneron no es efectivo en la variante omicron de COVID-19.

Los datos del Departamento de Salud y Servicios Humanos de EE. UU. (HHS) muestran que en la Región 4, que incluye el condado de Hendry, la variante dominante de COVID-19 es omicron en el 99,7 % de todos los casos, y la tasa actual de positividad de la comunidad supera el 40 %.

Siguiendo la orientación de la EAU de la FDA y la prevalencia de omicron en nuestra área, estamos suspendiendo las infusiones de Regeneron con efecto inmediato.

HRMC está trabajando diligentemente con entidades locales, estatales y federales para obtener tratamientos efectivos recientemente identificados y aprobados para el uso de infecciones leves a moderadas por la variante omicron de COVID-19.
 
 
COVID-19, omicron variant, Hendry Regional Medical Center, Regeneron monoclonal antibody infusion

Comments

x